Japan's Mochida Pharma To Expand Generic, Biosimilar Cancer Business
This article was originally published in PharmAsia News
Executive Summary
Mochida Pharmaceutical plans to expand its generics and biosimilars lines with an eye on building a $110.2 million-a-year business over the next three years, a rate double this year's expected earnings.
You may also be interested in...
China Poised To Conditionally Approve First COVID Vaccine
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Novartis Faces Another Challenge To Entresto In India
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Cosmetic And Personal Care Trademark Review 24 November, 2020
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Need a specific report? 1000+ reports available
Buy Reports